Valuation dashboard for Zimmer Biomet Holdings, Inc. (ZBH) with P/E 21.48, P/B 1.34, EV/EBITDA 12.33 and dividend yield 1.09%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific.
Analysis Summary
Zimmer Biomet Holdings, Inc. reported revenue of $8.23B in the most recent fiscal year, growing at a 5-year CAGR of 6.1%.
Trailing-twelve-month margins: gross margin 69.9%, operating margin 15.7%, net margin 9.5%.
At the current price of $88.29, ZBH trades at a P/E of 21.48 and an ROE of 6.36%. Market capitalisation stands at $17.1B, placing it among large-cap names.
Balance sheet quality for ZBH: current ratio of 2.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 21.48 |
| Price / Book | 1.34 |
| EV / EBITDA | 12.33 |
| Dividend Yield | 1.09% |
Valuation Models
| DCF Fair Value | $314.07 |
| vs Current Price | +255.7% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ZBH | Zimmer Biomet Holdings, Inc. | $17.1B | 21.48 | 1.34 | 6.4% |
| UTHR | United Therapeutics Corporation | $20.4B | 17.92 | 3.61 | 18.8% |
| DXCM | DexCom, Inc. | $32.2B | 33.74 | 12.49 | 36.2% |
| INCY | Incyte Corporation | $23.4B | 14.69 | 3.64 | 29.7% |
| ILMN | Illumina, Inc. | $41.3B | 50.94 | 14.53 | 31.2% |
| STE | STERIS plc | $20.3B | 25.49 | 2.82 | 11.3% |
| LH | Labcorp Holdings Inc. | $25.3B | 25.52 | 2.93 | 11.6% |
| DGX | Quest Diagnostics Incorporated | $25.7B | 24.76 | 3.41 | 14.5% |
Price
| Price | $88.29 |
| Market Cap | $17.1B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 6.36% |
| Return on Invested Capital | 5.51% |
| Return on Assets | 3.54% |
| Gross Margin | 69.87% |
| Operating Margin | 15.73% |
| Net Margin | 9.48% |
Related companies: DGX · DXCM · ILMN · INCY · LH · SNN · STE
Explore sector: Healthcare · Medical - Devices
More sections of ZBH: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks